{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:45:36Z","timestamp":1779212736042,"version":"3.51.4"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of episodic migraine (EM) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine has an enormous impact on a person's daily activities and quality of life, and results in significant clinical and economic burden to both individuals and society. It is important to understand the comparative efficacy and economic value of oral calcitonin gene\u2013related peptide receptor antagonists (gepants) for preventive treatment of EM. Currently, atogepant and rimegepant are US Food and Drug Administration approved for preventive treatment of migraine (rimegepant for EM and atogepant for EM and for chronic migraine). In the absence of head\u2010to\u2010head trials, we utilized an indirect treatment comparison on efficacy data from clinical trials conducted for the preventive treatment of EM. We estimated number needed to treat, a valuable metric used in clinical practice to compare treatment efficacy, and cost per additional responder, which can be used to establish the cost effectiveness of a treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An indirect treatment comparison was conducted to compare the efficacy of atogepant 60\u2009mg once daily and rimegepant 75\u2009mg once every other day as preventive treatments for EM using published data from the registrational trials of atogepant (ADVANCE) and rimegepant (BHV3000\u2010305). The efficacy outcome of interest was \u226550% reduction from baseline in mean monthly migraine\/headache days (\u226550% responder rate), which was variably defined for a base case and two scenario analyses. Number needed to treat and cost per additional responder versus placebo were calculated and compared between both treatments (weeks 9\u201312 in the base case analysis; weeks 1\u201312 and 9\u201312 for atogepant and during weeks 9\u201312 for rimegepant in the scenario analyses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the base case analysis, \u226550% responder rates were 64.9% (95% confidence interval [CI], 53.9\u201374.5) for atogepant and 51.8% (95% CI, 42.9\u201360.6) for rimegepant, compared to 44.1% (95% CI, 39.4\u201349.0) for placebo. The median number needed to treat versus placebo in the base case scenario was 4.8 (95% CI, 3.1\u20139.0) for atogepant compared to 13.0 (95% CI, 5.9\u201375.1) for rimegepant. The cost per additional responder versus placebo in the base case scenario was estimated to be $15,823 (95% CI, $11,079\u2013$29,516) for atogepant compared to $73,029 (95% CI, $32,901\u2013$422,104) for rimegepant. Results of the two scenario analyses were consistent with the base case analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Atogepant had substantially lower numbers needed to treat and costs per additional responder versus placebo than rimegepant for the preventive treatment of EM across all evaluated scenarios. These analyses suggest that atogepant may be more cost effective than rimegepant for the preventive treatment of EM. Limitations include differences in inclusion\/exclusion criteria and in reporting of the \u226550% responder rates between trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14824","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:15:26Z","timestamp":1725858926000},"page":"1253-1263","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine"],"prefix":"10.1111","volume":"64","author":[{"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"MedStar Georgetown University Hospital  Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav","family":"Gandhi","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana","family":"Lalla","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4280-4440","authenticated-orcid":false,"given":"Rashmi","family":"Halker Singh","sequence":"additional","affiliation":[{"name":"Mayo Clinic  Scottsdale Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology &amp; Headache  Stamford Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan H.","family":"Smith","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natty","family":"Chalermpalanupap","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Kelton","sequence":"additional","affiliation":[{"name":"Medical Decision Modeling Inc.  Indianapolis Indiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jefferson Headache Center Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00038-3"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12878"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420919098"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.18058"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20100"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00331-3"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1618830"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0813-3"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14386"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02163-3"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_12_21_1","unstructured":"QULIPTA [atogepant].Package Insert.AbbVie Inc.;2023. Accessed April 15 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215206Orig1s000lbl.pdf"},{"key":"e_1_2_12_22_1","unstructured":"NURTEC ODT [rimegepant].Package Insert.Pfizer Inc.;2023. Accessed April 15 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212728s009lbl.pdf"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035908"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01049-8"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00025-5"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01848-x"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00834-9"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989601"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418801579"},{"key":"e_1_2_12_31_1","unstructured":"AnalySource\u2014Premier Drug Pricing Services. Accessed April 15 2024.https:\/\/www.analysource.com\/"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.5455\/bcp.20150318073223"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12142"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.08.005"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00562-w"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0122"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14128"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241235156"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000205185"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_12_41_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","author":"Higgins JPT","year":"2023"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.08.019"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x12458724"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:55:02Z","timestamp":1762084502000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/head.14824"],"URL":"https:\/\/doi.org\/10.1111\/head.14824","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"2024-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}